X4 Pharmaceuticals (XFOR) Income from Continuing Operations (2017 - 2025)
X4 Pharmaceuticals (XFOR) posted Income from Continuing Operations of 23925000.0 for Q4 2025, up 19.76% on a QoQ basis from 29815000.0 in Q3 2025, and up 39.92% year-over-year from 17099223.31 in Q4 2024.
X4 Pharmaceuticals (XFOR) Income from Continuing Operations (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals' Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 23925000.0 for Q4 2025.
- Quarterly Income from Continuing Operations rose 39.92% year-over-year to 23925000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 79199000.0 (down 111.48% YoY) and the FY2025 annual result came in at 79199000.0, down 111.48% from the prior year.
- Income from Continuing Operations was 23925000.0 for Q4 2025 at X4 Pharmaceuticals, up from 29815000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 90833000.0 in Q2 2024 and bottomed at 55712000.0 in Q2 2023.
- A 5-year average of 20018950.0 and a median of 22945000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 263.04% in 2024, while the deepest fall reached 1492.02% in 2024.
- X4 Pharmaceuticals' Income from Continuing Operations stood at 30207000.0 in 2021, then increased by 3.65% to 29104000.0 in 2022, then jumped by 34.27% to 19130000.0 in 2023, then tumbled by 108.16% to 39821000.0 in 2024, then jumped by 39.92% to 23925000.0 in 2025.
- Business Quant data shows XFOR's Income from Continuing Operations at 23925000.0 in Q4 2025, 29815000.0 in Q3 2025, and 25741000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn | 205.99 Mn |
| 10 | X4 Pharmaceuticals | 166.21 Mn | -50.84 Mn | 2.20 Mn | -23.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23.93 Mn |
| Sep 30, 2025 | -29.82 Mn |
| Jun 30, 2025 | -25.74 Mn |
| Mar 31, 2025 | 282,000.00 |
| Dec 31, 2024 | -39.82 Mn |
| Sep 30, 2024 | -36.70 Mn |
| Jun 30, 2024 | 90.83 Mn |
| Mar 31, 2024 | -51.77 Mn |
| Dec 31, 2023 | -19.13 Mn |
| Sep 30, 2023 | -2.31 Mn |
| Jun 30, 2023 | -55.71 Mn |
| Mar 31, 2023 | -24.02 Mn |
| Dec 31, 2022 | -29.10 Mn |
| Sep 30, 2022 | -21.59 Mn |
| Jun 30, 2022 | -21.21 Mn |
| Mar 31, 2022 | -21.97 Mn |
| Dec 31, 2021 | -30.21 Mn |
| Sep 30, 2021 | -20.18 Mn |
| Jun 30, 2021 | -19.64 Mn |
| Mar 31, 2021 | -18.68 Mn |